ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ETX E-therapeutics Plc

11.30
0.15 (1.35%)
Last Updated: 10:07:29
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
E-therapeutics Plc LSE:ETX London Ordinary Share GB00B2823H99 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.15 1.35% 11.30 11.00 11.45 11.30 11.30 11.30 70,914 10:07:29
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 475k -8.27M -0.0142 -7.96 65.97M

e-Therapeutics plc Edison issues update on e-Therapeutics (ETX)

27/07/2017 4:46pm

RNS Non-Regulatory


TIDMETX

e-Therapeutics plc

27 July 2017

London, UK, 27 July 2017

Edison issues update on e-Therapeutics (ETX)

New CEO Dr Ray Barlow, who joined e-Therapeutics (ETX) in April, has undertaken a business and strategic review, assisted by an independent industry-wide expert panel. The portfolio has been rationalised from six to two preclinical immuno-oncology programmes; two programmes are available for out-licensing, while data will be published on two others to showcase and validate the proprietary network pharmacology discovery platform. This will secure ETX's cash runway comfortably to the end of 2019, free capacity to add new programmes in H217 and enable further investment in the platform. The management team is now focused on external collaborations and partnerships to provide validation and generate revenue. ETX's attendance at industry conferences, including one in Boston this week, will help to raise its profile.

No change to our numbers: cash of GBP14m (as of end-January 2017), tax credits (GBP2.8m received June 2017) and prudent cost control give ETX a secure cash runway to the end of 2019. However, deals remain key to unlocking value and the new team is focused on arranging meetings with potential collaborators. Attendance at industry conferences and data publication will raise the profile of the new management and the innovative discovery platform.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website

www.edisoninvestmentresearch.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Charlotte Hetzel, +44 (0)20 3077 5700

Linda Pomeroy, +44 (0)20 3077 5738

healthcare@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:

   LinkedIn        https://www.linkedin.com/company/edison-investment-research 
   Twitter           www.twitter.com/Edison_Inv_Res 
   YouTube       www.youtube.com/edisonitv 

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAOKODQPBKDBOB

(END) Dow Jones Newswires

July 27, 2017 11:46 ET (15:46 GMT)

1 Year E-therapeutics Chart

1 Year E-therapeutics Chart

1 Month E-therapeutics Chart

1 Month E-therapeutics Chart

Your Recent History

Delayed Upgrade Clock